Chongqing Zhifei Bio Products Financial Flexibility Index
Chongqing Zhifei Bio Products financial flexibility index. Chongqing Zhifei Bio Products (300122) has a Financial Flexibility Index of 0.10x as of September 2025. Free cash flow of CN¥1.62 Billion (operating CF CN¥1.42 Billion minus capex CN¥202.94 Million) represents 0% of total liabilities (CN¥16.79 Billion). See how much free cash does Chongqing Zhifei Bio Products generate to measure how efficiently the company converts operating cash flow to free cash.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of Chongqing Zhifei Bio Products (2007–2025)
Financial flexibility index of Chongqing Zhifei Bio Products from 2007 to 2025. Historical Financial Flexibility Index trend for Chongqing Zhifei Bio Products across 19 annual periods. Check earnings quality score of Chongqing Zhifei Bio Products to evaluate the quality of earnings relative to operating cash generation.
Chongqing Zhifei Bio Products Financial Flexibility Index by Year (2007–2025)
Chongqing Zhifei Bio Products financial flexibility index by year from 2007 to 2025. Year-by-year free cash flow to debt coverage for Chongqing Zhifei Bio Products. For the full cash flow conversion analysis, see Chongqing Zhifei Bio Products operating cash flow efficiency.
| Year | Flexibility Index | Free Cash Flow (CNY) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.37x | CN¥5.79 Billion | CN¥5.17 Billion | CN¥15.61 Billion | ▲ +303.0% |
| 2024 | -0.18x | CN¥-3.48 Billion | CN¥-4.41 Billion | CN¥19.08 Billion | ▼ -133.8% |
| 2023 | 0.54x | CN¥10.13 Billion | CN¥9.00 Billion | CN¥18.73 Billion | ▲ +116.4% |
| 2022 | 0.25x | CN¥3.44 Billion | CN¥1.99 Billion | CN¥13.77 Billion | ▼ -70.3% |
| 2021 | 0.84x | CN¥10.44 Billion | CN¥8.51 Billion | CN¥12.39 Billion | ▲ +35.9% |
| 2020 | 0.62x | CN¥4.32 Billion | CN¥3.50 Billion | CN¥6.97 Billion | ▲ +66.1% |
| 2019 | 0.37x | CN¥1.94 Billion | CN¥1.37 Billion | CN¥5.20 Billion | ▼ -7.8% |
| 2018 | 0.41x | CN¥1.07 Billion | CN¥585.59 Million | CN¥2.63 Billion | ▲ +9.0% |
| 2017 | 0.37x | CN¥434.46 Million | CN¥203.61 Million | CN¥1.17 Billion | ▼ -82.4% |
| 2016 | 2.11x | CN¥398.00 Million | CN¥89.95 Million | CN¥188.21 Million | ▼ 0.0% |
| 2015 | 2.11x | CN¥449.16 Million | CN¥223.45 Million | CN¥212.40 Million | ▲ +23.8% |
| 2014 | 1.71x | CN¥438.34 Million | CN¥161.39 Million | CN¥256.72 Million | ▼ -19.8% |
| 2013 | 2.13x | CN¥422.94 Million | CN¥221.58 Million | CN¥198.61 Million | ▼ -10.9% |
| 2012 | 2.39x | CN¥311.95 Million | CN¥112.89 Million | CN¥130.53 Million | ▼ -34.2% |
| 2011 | 3.63x | CN¥530.81 Million | CN¥221.25 Million | CN¥146.22 Million | ▲ +132.1% |
| 2010 | 1.56x | CN¥105.70 Million | CN¥54.19 Million | CN¥67.59 Million | ▼ -53.4% |
| 2009 | 3.35x | CN¥222.48 Million | CN¥210.61 Million | CN¥66.33 Million | ▲ +132.5% |
| 2008 | 1.44x | CN¥177.47 Million | CN¥141.58 Million | CN¥123.05 Million | ▲ +52.5% |
| 2007 | 0.95x | CN¥136.42 Million | CN¥111.66 Million | CN¥144.27 Million | — |